Normal view
-
cs.AI, q-bio.NC updates on arXiv.org
-
DGCPath: Distribution-Aware Generative Contrastive Framework for Self-supervised Path Representation Learning -- Extended Version
arXiv:2609.07316v2 Announce Type: replace Abstract: Due to the proliferation of vehicle trajectory data enabled by advanced sensing technologies, path representation learning has become a pivotal task in intelligent transportation systems. Although existing self-supervised approaches have achieved promising performance, their dependence on deterministic contrastive learning paradigms and handcrafted view augmentation strategies inherently restricts their cross-scenario generalization capabiliti
-
(Multiomics OR Omics) AND (Pancreatic)
-
GLP1-E2 therapy delays autoimmune diabetes in late-stage prediabetic NOD mice and potentiates low-dose anti-CD3 therapy for enhanced disease protection
Diabetologia. 2026 May 18. doi: 10.1007/s00125-026-06750-1. Online ahead of print.ABSTRACTAIMS/HYPOTHESIS: Anti-CD3 monoclonal antibody (aCD3) delays progression to stage 3 type 1 diabetes in high-risk individuals by modulating autoimmune activity. Nevertheless, responses remain variable and transient, with therapy providing only indirect beta cell protection. We investigated whether glucagon-like peptide-1-17ß-oestradiol conjugate (GLP1-E2), a beta cell-targeted fusion compound that enhances be
GLP1-E2 therapy delays autoimmune diabetes in late-stage prediabetic NOD mice and potentiates low-dose anti-CD3 therapy for enhanced disease protection
Diabetologia. 2026 May 18. doi: 10.1007/s00125-026-06750-1. Online ahead of print.
ABSTRACT
AIMS/HYPOTHESIS: Anti-CD3 monoclonal antibody (aCD3) delays progression to stage 3 type 1 diabetes in high-risk individuals by modulating autoimmune activity. Nevertheless, responses remain variable and transient, with therapy providing only indirect beta cell protection. We investigated whether glucagon-like peptide-1-17ß-oestradiol conjugate (GLP1-E2), a beta cell-targeted fusion compound that enhances beta cell survival and function, could potentiate a short low-dose aCD3 course in preventing autoimmune diabetes in NOD mice. We hypothesised that co-targeting immune dysregulation and beta cell fragility would provide complementary and potentially synergistic benefits, resulting in more durable protection than either monotherapy.
METHODS: Female late-stage prediabetic NOD mice were randomised into four groups: untreated controls, aCD3 monotherapy, GLP1-E2 monotherapy and combination therapy. aCD3 was administered intravenously at 2.5 µg/day for 5 consecutive days, while GLP1-E2 was given subcutaneously at 100 nmol kg-1 day-1 for 18 weeks. Mice were monitored longitudinally for diabetes onset. The pancreas was analysed by spatial transcriptomics and immunostaining to assess immune infiltration, beta cell integrity and molecular pathway alterations.
RESULTS: At 30 weeks of age, diabetes incidence was 77% in untreated controls, 66% in mono aCD3-treated mice and 61% in mono GLP1-E2-treated mice. Combination therapy significantly reduced diabetes incidence to 38% (p≤0.001) and delayed disease onset by 6 weeks, with sustained protection persisting for 5 weeks after treatment cessation. GLP1-E2 monotherapy reduced islet immune cell infiltration to a similar extent as aCD3 mono- and combination therapy, without affecting peripheral lymphocyte counts. Spatial transcriptomics showed increased gene responses linked to beta cell stress (Hspa5, Eif2ak3, Xbp1, Ddit3), dedifferentiation (Cd81), 'disallowed' genes (Oat, Igfbp4), antigen presentation (H2-K1, H2-Q6, H2-Ab1, H2-Eb1) and inflammation (Cxcl10, Cxcl9, Ccl5) during disease progression. These processes were attenuated by mono- and combination therapy, with aCD3 mostly restoring beta cell identity and GLP1-E2 reducing beta cell stress and immunogenicity. Staining for CD81 and TUNEL in 17-week-old treated mice revealed levels comparable to 12-week-old normoglycaemic NOD mice, while being increased in 17-week-old untreated mice. This reduced beta cell dedifferentiation and death was associated with improved beta cell protection and better preservation of beta cell mass at 26.5 weeks compared with new-onset (diabetic) mice.
CONCLUSIONS/INTERPRETATION: Low-dose aCD3 or GLP1-E2 monotherapy delayed diabetes onset and preserved beta cell mass in female NOD mice, while the combination provided substantially superior protection. Simultaneously targeting immune dysregulation and beta cell vulnerability highlights the potential of combination therapy to enhance and prolong immunotherapeutic efficacy in type 1 diabetes.
PMID:42149241 | DOI:10.1007/s00125-026-06750-1
-
cs.AI, q-bio.NC updates on arXiv.org
-
ARROW: An Adaptive Rollout and Routing Method for Global Weather Forecasting
arXiv:2510.09734v2 Announce Type: replace-cross Abstract: Weather forecasting is a fundamental task in spatiotemporal data analysis, with broad applications across a wide range of domains. Existing data-driven forecasting methods typically model atmospheric dynamics over a fixed short time interval, e.g., 6 hours, and rely on naive autoregression-based rollout for long-term forecasting, e.g., 5 days. However, this paradigm suffers from two key limitations: (1) it often inadequately models the s
ARROW: An Adaptive Rollout and Routing Method for Global Weather Forecasting
-
cs.AI, q-bio.NC updates on arXiv.org
-
FedBPrompt: Federated Domain Generalization Person Re-Identification via Body Distribution Aware Visual Prompts
arXiv:2603.12912v1 Announce Type: cross Abstract: Federated Domain Generalization for Person Re-Identification (FedDG-ReID) learns domain-invariant representations from decentralized data. While Vision Transformer (ViT) is widely adopted, its global attention often fails to distinguish pedestrians from high similarity backgrounds or diverse viewpoints -- a challenge amplified by cross-client distribution shifts in FedDG-ReID. To address this, we propose Federated Body Distribution Aware Visual
FedBPrompt: Federated Domain Generalization Person Re-Identification via Body Distribution Aware Visual Prompts
-
cs.AI, q-bio.NC updates on arXiv.org
-
GCGNet: Graph-Consistent Generative Network for Time Series Forecasting with Exogenous Variables
arXiv:2603.08032v1 Announce Type: cross Abstract: Exogenous variables offer valuable supplementary information for predicting future endogenous variables. Forecasting with exogenous variables needs to consider both past-to-future dependencies (i.e., temporal correlations) and the influence of exogenous variables on endogenous variables (i.e., channel correlations). This is pivotal when future exogenous variables are available, because they may directly affect the future endogenous variables. Ma
GCGNet: Graph-Consistent Generative Network for Time Series Forecasting with Exogenous Variables
-
cs.AI, q-bio.NC updates on arXiv.org
-
ST-EVO: Towards Generative Spatio-Temporal Evolution of Multi-Agent Communication Topologies
arXiv:2602.14681v2 Announce Type: replace-cross Abstract: LLM-powered Multi-Agent Systems (MAS) have emerged as an effective approach towards collaborative intelligence, and have attracted wide research interests. Among them, ``self-evolving'' MAS, treated as a more flexible and powerful technical route, can construct task-adaptive workflows or communication topologies, instead of relying on a predefined static structue template. Current self-evolving MAS mainly focus on Spatial Evolving or Tem
ST-EVO: Towards Generative Spatio-Temporal Evolution of Multi-Agent Communication Topologies
-
cs.AI, q-bio.NC updates on arXiv.org
-
ST-EVO: Towards Generative Spatio-Temporal Evolution of Multi-Agent Communication Topologies
arXiv:2602.14681v1 Announce Type: cross Abstract: LLM-powered Multi-Agent Systems (MAS) have emerged as an effective approach towards collaborative intelligence, and have attracted wide research interests. Among them, ``self-evolving'' MAS, treated as a more flexible and powerful technical route, can construct task-adaptive workflows or communication topologies, instead of relying on a predefined static structue template. Current self-evolving MAS mainly focus on Spatial Evolving or Temporal Ev